Member Info for TorquayFan

Allogene astounds Wall Street with $324m IPO to fund cell therapy R&D :-

''Great things were expected of Allogene Therapeutics’ IPO this week – the company is led by Arie Belldegrun and David Chang, who masterminded development and approval of Kite Pharma’s CAR-T cancer therapy before selling the company to Gilead for $12 billion.

The company had already raised more than $400 million in two private funding rounds to develop its ‘off-the-shelf’ CAR-T therapy and had been planning to raise $287 million from its debut on Wall Street. But the IPO this week exceeded even this ambitious target, raising $324 million on Wednesday, with shares rising by 30% on the first day of trading.''
and . . . ''What has excited investors so much about Allogene is the potential of its allogeneic CAR-T therapies, which are derived from a bank of cells instead of being manufactured from a patient’s own T-cells, a costly and time-consuming process.''

https://pharmaphorum.com/top-stories/allogene-astounds-wall-street-with-324m-ipo-to-fund-cell-therapy-rd/

Ruck - you know the stuff about 'half full or empty' ? You and some others have a hole in the bucket !

Good to see Scancell talking again next month although I'm surprised Scancell have the time . . .

Inan it's good to see you bouncing and there's much in what you say !

https://www.proactiveinvestors.co.uk/register/event_details/174 (Thanks Aim-Trader).

Well said that Man !
Most of us think your conclusion would be fair enough - yet 9.75 pence ?

(btw inflection with an L) ATB

C7 thanks for that reminder of JG's Aug 14th tweet.
I'm sure it's not been forgotten. Some dismay that after another 2 months have passed without any further updates, yet . . . . . Hoping for a better week to say the least !

HR - I hope Hanoi Rocks won't be playing live at the £1 Party - on that clip, the Guy in the red trousers playing guitar actually spits ! A lot. Yuk !

He should be playing EPL with that talent. ATB.

C7 I guess there's only the one band named ''Hanoi Rocks''- perhaps the track 'Tragedy' would be suitable for a £1 party ? If it's only the £1 to celebrate !

https://www.youtube.com/watch?v=aM4BqmRA9WM

Nice day all . .

Hi. Just noticed yours but I am on my way out the door. I hope someone else can help you. Good to get another angle anyway . . . .

Maybe your arrival is a good Omen - I see some BLUE ! ATB

I happen to be 'on seat' atm so welcome !

Q. How unique is the science ? A. Immunobody and Moditope platforms have significant Patents - so the science is as unique as it needs to be for that.

Q. Other Company's in this space ? A. Of course - many hundreds - it's a potential $100 billion + p.a. market. But we are hopeful that coming trials will prove Immunobody greatly enhances the use of 'Checkpoint Inhibitors', atm the leading new treatment, in the next 12 months or so. Also Moditope may then reduce the need for 'CI' if the Clinical reflects the indications so far.

Q. What makes us unique or the one to invest in ? A. I think you have to reach your own decision.

Q. Commercialisation ? A. Tomorrow? 12 months? Who knows? But a.s.a.p. please !

Q. Is it only for a limited number of cancers? A. If you watched the Scancell presentation, Feb 16th, did you see Prof. Lindy say she would like to cure all cancers. Many many cancers are already targeted - some one else might give you more on this.

Lotta questions there M8. Hope this helps. ATB

So MD Anderson have now established in a trial, some confidence in a Combo of vaccine / CI. It'll be good when we see a similar report on SCIB1 / Keytruda Combo . . . roll on the day !

'' ''A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology. “That encouraging response rate is about twice the rate produced by PD1 checkpoint inhibitors in previous clinical trials, so these results will lead to larger, randomized clinical trials of this combination,” said principal investigator Bonnie Glisson, M.D., professor of Thoracic/Head and Neck Medical Oncology and Abell-Hanger Foundation Distinguished Professor at MD Anderson.''''

Thanks Gooosed.

https://www.mdanderson.org/newsroom/2018/09/vaccine-anti-pd1-drug-show-promise-against-incurable-hpv-related-cancers.html

So MD Anderson have now established in a trial, some confidence in a Combo of vaccine / CI. It'll be good when we see a similar report on SCIB1 / Keytruda Combo . . . roll on the day !

'' ''A tumor-specific vaccine combined with an immune checkpoint inhibitor shrank tumors in one third of patients with incurable cancer related to the human papilloma virus (HPV) in a phase II clinical trial led by investigators at The University of Texas MD Anderson Cancer Center and reported in JAMA Oncology. “That encouraging response rate is about twice the rate produced by PD1 checkpoint inhibitors in previous clinical trials, so these results will lead to larger, randomized clinical trials of this combination,” said principal investigator Bonnie Glisson, M.D., professor of Thoracic/Head and Neck Medical Oncology and Abell-Hanger Foundation Distinguished Professor at MD Anderson.''''

Thanks Gooosed.

https://www.mdanderson.org/newsroom/2018/09/vaccine-anti-pd1-drug-show-promise-against-incurable-hpv-related-cancers.html

After 08.12 that's an odd rebuke !

There's been some rational chat on the BB over the last few days so what's up Doc ?

If 'sentiment' is low - news would cure that. Or even an update on progress. That's all.

It's 37C here now and I have to cycle 5km to pick up my truck ! BFN TCOY

I hope you'll get other replies but I seem to remember that Ichor had completed their paperwork for the Ichor 2 which was integral to the IND submission the progress of which we don't know ?

Thanks for the link . .

News today ?

I hope you'll get other replies but I seem to remember that Ichor had completed their paperwork for the Ichor 2 which was integral to the IND submission the progress of which we don't know ?

Thanks for the link . .

News today ?

That's a very 'Footballist' comment !
And not Tony's Bruv shurely . . . .

Talented Guy I suspect . . . News please . . .

Thanks - no problem with that. I've picked out some bits from the RNS :-

''Cancer Research UK will fund and sponsor a UK-based Phase 1/2 clinical trial of SCIB2 in combination with a checkpoint inhibitor in patients with solid tumours, focusing on NSCLC in the first instance. The charity's Centre for Drug Development (CDD) will be responsible for manufacturing the clinical trial supplies of SCIB2, conducting pre-clinical testing, sponsoring and managing the clinical trial, including the clinical trial timelines.''

and . . . . . .

''The charity's world-renowned expertise will no doubt be invaluable as we progress SCIB2 through the clinic.''

I think we both have a point - whilst Prof. Lindy will be the main point of reference, all this suggests to me that CRUK will take on quite a lot of the workload.

Most importantly :-

'' ''Dr Nigel Blackburn, Cancer Research UK's director of drug development, said: "We're excited to be giving our extensive expertise and experience in drug development to move this immunotherapy treatment into the clinic.
This collaboration will ensure that this innovative vaccine reaches patients sooner and could bring about urgently needed improvements for some cancers which can be hard to treat, including lung cancer - a disease where survival rates remain stubbornly low." ''

Reaching Patients sooner ! That sounds confident. ATB

Chester your 14.46 yesterday - post rec. Your first para is very much on target IMH - my analogy for this is trying to move all these Elephants' of science forward at the same time. Despite the mindboggling workload the amazing Prof. Lindy and her amazing team have managed to keep taking the science forward - on all fronts.

One of the best happenings IMH has been CRUK taking on SCIB2 development - that should free up some resource inside Scancell's team.

At the AGM some matters of progress to trials will certainly be clarified - that's inevitable. There is a genuine beef here about communication (now agree with that C7) and at AGM they must surely say something helpful !

I'm holding but after 7 years - happy would be nice too ! ATB

The timetables - you might be right - but in that case - why have we not been informed by BoD about SCIB1 Combo progress ? Is it Mr Glencross's role ?

I agree with Boris and JRM and DD etc and Barry Goldwater about the EU and the need to exit asap.
On another Forum I enjoy - the EU hit squad are 'monikered' - the Ayatollahs !
Maybe I didn't get the irony right in the first post ? Again !

Re Konar and Buck, well I like to see both sides of a discussion (except Brexit) and can see bits here and there on both sides. Don't wanna sound too virtuous there - but on some things - I can see the point being made.

Anyway you old bigger, it's my bedtime. You've been missed . . . .

Your 12.54. ''Nobody is engaging with this BB'' - YES they are . . . . Welcome back . . . .
(Jeepers - 25 posts is my longest read for a while).

Seriously it is right to ask at AGM about timescales and RG/JC emols too. I'm sure the BoD will have the answers ?

SCIB1 is on time as we were tweeted by John Glencross - but why have we not been told directly - by BoD - of that fact or why there is a delay ?

As for Brexit - high jinks - I'm a Jacob R-M man - that's not surprising - lots of talent in the West Country.

Ruck Rover, Konar and WF - great posts. IMVVHO.

Inan - we do it just to flush you out into the open ! I'm guessing that you are just as frustrated as Konar ?
Anyway - what's wrong with Chequers ? LOL Go Theresa !

Konar - yes that's a long delay - moving all these elephants of science forward at the same time is not easy. As for a question at the AGM - yep - that's a nice one. Would be good to hear how it is answered . . .

If scientists can coax T-cells into expressing the neoantigens, then they will be able to create a therapy personalised to the individual patient’s cancer.

https://pharmaphorum.com/top-stories/gilead-signs-biotech-deal-arming-t-cells-to-attack-solid-tumours/